InvestorsHub Logo
Followers 57
Posts 5697
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Tuesday, 02/07/2017 6:13:03 PM

Tuesday, February 07, 2017 6:13:03 PM

Post# of 6035
The low cost/high benefit of the gp96 platform is important. Cost/ benefit analysis will be important in the future. This article is very interesting...
http://www.clinicaloncology.com/Current-Practice/Article/01-17/Immunotherapy-May-Need-To-Have-Its-Own-Value-Model/40164?ses=ogst

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News